Pavan Cheruvu
CEO & DirectorDr. Pavan Cheruvu, MD., is CEO & Director of Amanat Acquisition Corp from May 18, 2026. Dr. Cheruvu is Chairman of the Board of Imbria Pharmaceuticals, Inc. from September 2025. Dr. Cheruvu is Independent Director of Retension Pharmaceuticals, Inc. from October 8, 2026. He served as the CEO of Bitterroot Bio, Inc. from March 2022 to February 2026 and had served as its President and Director until 2026. He served as Chief Executive Officer of Sio Gene Therapies, Inc. since November 2020 until January 2022 and served as its Director since September 26, 2018 until January 2022 and served as its President until January 2022. He served as Principal Executive Officer of Axovant Gene Therapies Ltd. (formerly known as Axovant Sciences Ltd.) since February 12, 2018 until November 2020. Dr. Cheruvu provides medical oversight for Hale’s work in cardiovascular health. He serves as an General Cardiology fellow at UCSF’s Cardiac Catheterization Laboratory. Prior to joining Axovant, Dr. Cheruvu held roles of increasing responsibility at Roivant and supporting Axovant since 2015 and was appointed to the Roivant executive leadership team in 2017. A board-certified physician, Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training in a clinical fellowship in cardiovascular medicine at the University of California, San Francisco. Prior to joining Axovant, Dr. Cheruvu worked at RSI since October 2015 and was appointed to RSI’s executive leadership team in September 2017. Prior to his medical training, Dr. Cheruvu was a management consultant at McKinsey & Company from June 2008 to June 2011, where he focused on biopharmaceutical strategy. He earned his B.S.E. in Biomedical Engineering, B.S.E. in Electrical Engineering and A.B. in Chemistry from Duke University summa cum laude, his M.Sc. in Computer Science from Oxford University where he was a Rhodes Scholar and his M.D. from Harvard Medical School and the Massachusetts Institute of Technology.
Positions
- Company NameAmanat Acquisition CorpStock CodeAMANPositionCEO & Director
